UPCC 35217: A Phase 1B/2 Open label study of Niraparib plus either Ipilimumab or Nivolumab in patients with advanced Pancreatic Cancer who have achieved stability on platinum- based therapy

The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib with either ipilimumab or nivolumab on patients and their pancreatic cancer.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Pancreatic Adenocarcinoma
• Age: - 99 Years
• Gender: All